S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

• Status: Active, not recruiting
• Trial end date: 2022-10-01

Summary

The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.

• Phase: Phase 2

Details

• Lead Sponsor: Southwest Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cisplatin; Doxorubicin; Gemcitabine; Lenograstim; Liposomal doxorubicin; Methotrexate; Vinblastine